Literature DB >> 9264156

Pathogenetic role, in human and murine tuberculosis, of changes in the peripheral metabolism of glucocorticoids and antiglucocorticoids.

G A Rook1, R Hernandez-Pando.   

Abstract

Immunity to tuberculosis (TB) requires a Th1 pattern of cytokine release, dominated by interleukin-2 (IL-2) and interferon gamma (IFN gamma). In experimental models even a minor Th2 component (characterized by production of IL-4) abrogates immunity, and leads to an immunopathology that mimics the human disease. Increased exposure of T cells to glucocorticoids drives them towards a Th2 cytokine profile and could therefore help to explain the presence of an inappropriate Th2 component in TB. Analysis of adrenal steroid metabolites in 24-h urine collections revealed a striking increase in metabolites of active cortisol relative to metabolites of inactive cortisone. This indicates a change in the balance of 11 beta-hydroxysteroid dehydrogenase to 11 beta-ketosteroid reductase. The site of this disease-associated alteration in reductase/dehydrogenase balance may be the lung. The lung contains 11 beta HSD-1, (a reversible oxido-reductase) which in the liver works as a reductase. In the normal lung it functions paradoxically as a reductase, but it can alter its function in the presence of cytokines. TB patients (like other ill individuals) also show reduced 24-h urinary secretion of dehydroepiandrosterone (DHEA) derivatives. Since these have antiglucocorticoid functions in vivo, this fall may exacerbate the effects of the reduced inactivation of cortisol and loss of diurnal rhythm, and contribute to immunological dysfunction. Recent studies of TB in mice, and in children during infancy, adrenarche and puberty, suggest that the ratio of cortisol to DHEA may be crucial both to susceptibility and to the pathology of the disease that develops.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264156     DOI: 10.1016/s0306-4530(97)00014-0

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  6 in total

1.  Mycobacterial glycolipid cord factor trehalose 6,6'-dimycolate causes a decrease in serum cortisol during the granulomatous response.

Authors:  Jeffrey K Actor; Jessica Indrigo; Christopher M Beachdel; Margaret Olsen; Alice Wells; Robert L Hunter; Amitava Dasgupta
Journal:  Neuroimmunomodulation       Date:  2002 -2003       Impact factor: 2.492

2.  Tuberculosis, deprivation, and ethnicity in Leeds, UK, 1982-1997.

Authors:  R Parslow; N A El-Shimy; D B Cundall; P A McKinney
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

3.  IL-6 mediates 11βHSD type 2 to effect progression of the mycobacterial cord factor trehalose 6,6'-dimycolate-induced granulomatous response.

Authors:  April N Abbott; Kerry J Welsh; Shen-An Hwang; Paulina Płoszaj; Tina Choudhury; Sydney Boyd; Michael R Blackburn; Robert L Hunter; Jeffrey K Actor
Journal:  Neuroimmunomodulation       Date:  2011-03-08       Impact factor: 2.492

4.  How "humane" is your endpoint? Refining the science-driven approach for termination of animal studies of chronic infection.

Authors:  Nuno H Franco; Margarida Correia-Neves; I Anna S Olsson
Journal:  PLoS Pathog       Date:  2012-01-19       Impact factor: 6.823

5.  16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment.

Authors:  Manuel Othoniel López-Torres; Brenda Marquina-Castillo; Octavio Ramos-Espinosa; Dulce Mata-Espinosa; Jorge A Barrios-Payan; Guillermina Baay-Guzman; Sara Huerta Yepez; Estela Bini; Ivan Torre-Villalvazo; Nimbe Torres; Armando Tovar; William Chamberlin; Yu Ge; Andrea Carranza; Rogelio Hernández-Pando
Journal:  Clin Exp Immunol       Date:  2021-06-01       Impact factor: 5.732

6.  Analysis of 30 patients with acupuncture-induced primary inoculation tuberculosis.

Authors:  Yangbo Liu; Jingye Pan; Keke Jin; Cailong Liu; Jing Wang; Li Chen; Lei Chen; Jiandong Yuan
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.